The baseline situation: A 60-year-old female, without any personal or family history of autoimmune and endocrine diseases, was diagnosed with squamous cell carcinoma of the urethral meatus with inguinal lymph node metastasis and was treated with camrelizumab (anti-PD1, 200mg every 3 weeks) 14 times combined with anlotinib hydrochloride capsules (12mg/day) at regular intervals from February to December 2020. Here, PDCD1 is linked to squamous cell carcinoma.